Q-omics provides the consensus-scored ZNF564 profile across patient tissues and cancer cell-line models. ZNF564 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF564 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, ZNF564 RNA expression shows 21,241 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, THCA, and UVM as cancer lineages where ZNF564 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF564 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF564 survival associations across molecular data types. ZNF564 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF564 RNA expression–survival associations across cancer types. High ZNF564 expression shows unfavorable associations in LUSC and KICH, but favorable associations in HNSC, KIRC, UCS and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF564 RNA expression.
This table summarizes ZNF564 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF564. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF564 shows lower tumor expression in THCA, COAD and KIRC and higher tumor expression in LIHC, BLCA and BRCA. The THCA box plot shows higher ZNF564 RNA expression in normal versus tumor tissue (log2 FC = −0.600, t-test p < 0.001).
This table shows molecular features associated with ZNF564 in patient tissues and cancer cell lines. In patient samples, ZNF564 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF564 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LUNG_SCLC.
